Zenas BioPharma, Inc.
ZBIODrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How ZBIO's past catalysts played out
Obexelimab
IgG4 Related Disease
Orelabrutinib
Multiple Sclerosis (MS) Primary Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obexelimab | Phase 3 | IgG4 Related Disease | - | - |
Orelabrutinib | Phase 3 | Multiple Sclerosis (MS) Primary Progressive | - | - |
Frequently asked questions
What is in Zenas BioPharma, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Zenas BioPharma, Inc.'s (ZBIO) pipeline across Phase 3. Its lead program is Obexelimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zenas BioPharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Zenas BioPharma, Inc. (ZBIO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ZBIO biotech catalysts?→
Add ZBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zenas BioPharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.